Regulatory approval

Published by the Health Service Executive. Approved

The Republic of Ireland's Health Service Executive (HSE) has approved cyclophosphamide in combination with doxorubicin, vincristine, and prednisolone (mini-CHOP Therapy) (21 days) for the treatment of non-hodgkin lymphoma (NHL) in patients aged greater than 80 or with significant co-morbidities. The therapy regimen further states that rituximab is to be included for the treatment of CD20 positive patients.

This is written in the approval document as:

Treatment of Non Hodgkin Lymphoma in patients aged greater than 80 or with significant co-morbidities. Rituximab to be included in all CD20 positive patients.

Reimbursement

Hospital

Citation

(R*)- miniCHOP Therapy - 21 days, 2024, version number 4a, NCCP National SACT Regimen, viewed 26/03/2026, https://healthservice.hse.ie/documents/6472/436_v4a_R-miniCHOP.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HSE (1)	CD20 +	Non-Hodgkin Lymphoma	Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab, Vincristine

Contributions

Date	Contributor	Description
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2018-11-05	Health Service Executive	Indication approved for reimbursement.